Ganirelix Acetate (ganirelix acetate)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Ganirelix acetate, a synthetic decapeptide analog of naturally occurring gonadotropin-releasing hormone (GnRH, luteinizing hormone-releasing hormone, gonadorelin), is a GnRH antagonist.
Ganirelix acetate, a synthetic decapeptide analog of naturally occurring gonadotropin-releasing hormone (GnRH, luteinizing hormone-releasing hormone, gonadorelin), is a GnRH antagonist.
Ganirelix competitively blocks GnRH receptors on the pituitary gonadotroph and the subsequent transduction pathway, inducing a rapid, reversible suppression of gonadotropin (luteinizing hormone (LH), follicle-stimulating hormone (FSH)) secretion. The suppression of pituitary LH secretion by ganirelix is more pronounced than that of FSH. Associated decreases in sex hormones (e.g., estradiol, testosterone) occur.
By suppressing the midcycle GnRH-induced surge in LH, ganirelix can suppress ovulation, oocytic meiosis, and luteinization. In women undergoing controlled ovarian hyperstimulation, the drug can prevent the LH surges associated with such stimulation and improve implantation and pregnancy rates associated with in vitro fertilization. Following discontinuance of the drug, pituitary LH and FSH secretion fully recovers within 48 hours.
In women with normal ovulatory menstrual cycles, ovarian function resumes rapidly following discontinuance of ganirelix, with resumption of menses within several weeks.
USES: This medication is used by women having certain fertility treatments (controlled ovarian stimulation). Ganirelix is usually used in combination with other hormones (FSH and hCG). It works by blocking the release of a certain hormone (luteinizing hormone).
Ganirelix stops eggs from being released too early and gives the eggs time to grow properly.
Generic name: ganirelix acetate
Pronunciation: (GAN-i-REL-ix AS-e-tate)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Ganirelix Acetate
Indications
The following indications are listed for Ganirelix Acetate:
- Prevention Of Luteinizing Hormone Surge When Undergoing Controlled Ovarian Hyperstimulation
Also known as: Prevention Of Lh Surge In Coh, Prophylaxis Of Luteinizing Hormone Surge When Undergoing Controlled Ovarian Hyperstimulation.
Dosing
The recommended dosage of ganirelix acetate for the inhibition of premature LH surges in adult women undergoing controlled ovarian hyperstimulation (with an exogenous form of FSH) is 250 mcg once daily during the mid- to late-follicular phase of the menstrual cycle. FSH therapy (e.g., follitropin beta) usually is initiated on the morning of day 2 or 3 of the menstrual cycle and ganirelix acetate on the morning of day 7 or 8 of the cycle (day 6 of FSH therapy) and continued until an adequate follicular response is achieved, at which time human chorionic gonadotropin (hCG) is administered and FSH therapy and ganirelix are discontinued. Oocyte retrieval, followed by in vitro fertilization or intracytoplasmic sperm injection, is then performed, with subsequent attempts at implantation and pregnancy.
Ganirelix acetate is administered by subcutaneous injection once daily. The currently available formulation is for subcutaneous use only.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
No formal drug interaction studies have been performed.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
Known hypersensitivity to ganirelix or any ingredient in the formulation. Known hypersensitivity to GnRH or any other GnRH analog. Known or suspected pregnancy.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
Adverse effects of ganirelix occurring in at least 1% of treated individuals include neutrophil count of 8.3/mm3 or greater, gynecologic abdominal pain, fetal death, headache, ovarian hyperstimulation syndrome, vaginal bleeding, injection site reactions, nausea, and GI abdominal pain.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
Not indicated.
Category X. (See Users Guide.) May result in fetal loss due to antigonadotropic properties. (See Cautions: Contraindications and also Major Toxicities.)
It is unknown whether ganirelix is distributed in breast milk; use in nursing women is not recommended.
Clinical studies did not include sufficient numbers of geriatric adults 65 years of age or older.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.